Controversies in medicine: redefining the diagnosis of type 1 diabetes

Jennifer J Couper and Leonard C Harrison
Med J Aust 2019; 211 (4): . || doi: 10.5694/mja2.50284
Published online: 19 August 2019

Diagnosis of autoimmune β-cell disorder before end-stage clinical type 1 diabetes is a key step towards the prevention of this disease

  • 1 Women's and Children's Hospital, Adelaide, SA
  • 2 University of Adelaide, Adelaide, SA
  • 3 Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC


We acknowledge the contributions to the manuscript of Megan Penno and the community support and perspective provided by Juvenile Diabetes Research Foundation Australia, the recipient of the Australian Research Council Special Research Initiative in Type 1 Diabetes. Leonard Harrison was supported by a National Health and Medical Research Council Senior Principal Research Fellowship (1080887).

Competing interests:

No relevant disclosures.

  • 1. Haynes A, Bulsara MK, Bower C, et al. Regular peaks and troughs in the Australian incidence of childhood type 1 diabetes mellitus (2000–2011). Diabetologia 2015; 58: 2513–2516.
  • 2. Phelan H, Clapin H, Bruns L, et al. The Australasian Diabetes Data Network: first national audit of children and adolescents with type 1 diabetes. Med J Aust 2017; 206: 121–125.
  • 3. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473–2479.
  • 4. Raab J, Haupt F, Scholz M, et al. Capillary blood islet autoantibody screening for identifying pre‐type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 2016; 6: e11144.
  • 5. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society and the American Diabetes Association. Diabetes Care 2015; 38: 1964–1974.
  • 6. Colman PG, McNair P, Margetts H, et al. The Melbourne Pre‐Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. Med J Aust 1998; 169: 81–84.
  • 7. Bonifacio E, Mathieu C, Nepom GT, et al. Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia 2017; 60: 35–38.
  • 8. Department of Health. Australian National Diabetes Strategy 2016–2020. Canberra: Commonwealth of Australia, 2015. (viewed Jan 2019).
  • 9. King BR, Howard NJ, Verge CF, et al. A diabetes awareness campaign prevents diabetic ketoacidosis in children at their initial presentation with type 1 diabetes. Pediatr Diabetes 2012; 13: 647–651.
  • 10. Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long‐term glycemic control. Diabetes Care 2017; 4: 1249–1255.
  • 11. Winkler C, Schober E, Ziegler AG, Holl RW. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 2012; 13: 308–313.
  • 12. Steck AK, Larsson HE, Liu X, et al. Residual beta‐cell function in diabetes children followed and diagnosed in the TEDDY study compared with community controls. Pediatr Diabetes 2017; 18: 794–802.
  • 13. Gesualdo PD, Bautista KA, Waugh KC, et al. Feasibility of screening for T1D and celiac disease in a pediatric clinic setting. Pediatr Diabetes 2016; 17: 441–448.
  • 14. Smith LB, Liu X, Johnson SB, et al. Family adjustment to diabetes diagnosis in children: can participation in a study on type 1 diabetes genetic risk be helpful? Pediatr Diabetes 2018; 19: 1025–1033.
  • 15. Herold KC, Bundy BN, Long A, et al. An anti‐CD3 antibody, teplizumab, in relatives with type 1 diabetes. N Engl J Med 2019. [Epub ahead of print]
  • 16. Bingley PJ, Bonifacio E, Williams AJ, et al. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46: 1701–1710.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.